Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder

Authors
Shin, CheolminPae, Chi-UnKwak, Kyung PhilJeon, Sang WonJeong, Hyun-GhangKim, Jong-WooLee, Youn JungPatkar, Ashwin A.Han, Changsu
Issue Date
5월-2021
Publisher
KOREAN COLL NEUROPSYCHOPHARMACOLOGY
Keywords
Residual symptom; Major depressive disorder; Antidepressant; Aripiprazole augmentation
Citation
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.19, no.2, pp.243 - 253
Indexed
SCIE
SCOPUS
KCI
Journal Title
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
Volume
19
Number
2
Start Page
243
End Page
253
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/128126
DOI
10.9758/cpn.2021.19.2.243
ISSN
1738-1088
Abstract
Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual symptoms in the patients with partially remitted MDD. Methods: We retrospectively analyzed the 8-week medical records of the patients. The enrolled patients did respond to treatment of antidepressant but were not remitted. The range of 17-item Hamilton Depression Rating Scale (HAMD) total score of the subjects were 8 to 15 points. All patients were currently taking antidepressants when they started aripiprazole. The primary endpoint was the mean change of Clinically Useful Depression Outcome Scale (CUDOS). Secondary endpoint measures were HAMD, Clinical Global Impression-severity (CGI-S) scores, Patient Health Questionnaire-15 (PHQ-15), Beck Anxiety Inventory (BAI), Perceived Deficit Questionnaire-depression (PDQ-D), Sheehan Disability Scale (SDS) and General Health Questionnaire/Quality of Life-12 (GHQ/QL-12). Results: A total of 134 medical records were analyzed. The changes of CUDOS, HAMD, CGI-S, BAI, PHQ-15, PDQ-D, SDS and GHQ/QL-12 from baseline to the endpoint were -7.93, -3.29, -0.80, -4.02, -2.05, -4.35, -4.77 and -2.82, respectively (all p < 0.001). At the endpoint, the newly remitted subjects rate by HAMD score criteria were approximately 46%. Conclusion: Our preliminary findings have presented the effectiveness of aripiprazole augmentation for residual symptoms of partially remitted MDD patients in routine practice. This study assures subsequent well-controlled studies of the possibility of generalizing the above promising outcome in the future.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Han, Chang su photo

Han, Chang su
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE